《本地樓市》日出康城「凱柏峰I」次輪累收逾3,400票 超購13.3倍
信置(00083.HK)、嘉華國際(00173.HK)及招商局置地(00978.HK)合作發展的港鐵(00066.HK)日出康城第11B期住宅項目「凱柏峰I」上周四(6月30日)首輪銷售,全數238伙即日沽清,套現逾19億元。項目將於本周四(7月7日) 次輪開售238伙,以價單計市值逾24億元。
截止今日(4日)下午3時半,項目第二輪銷售累積收逾3,400票,超購13.3倍。次輪推出238伙,扣除最高16%折扣,折實價由643.86萬元至1,300.48萬元,折實呎價17,106元至21,346元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.